401.3 Extracellular vesicle microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ post-transplant lymphoproliferative disorder
Tuesday March 28, 2023 from 08:00 to 09:00
Hill Country AB
Presenter

Ayantika Sen, United States

Postdoctoral Researcher

Division of Abdominal Transplant

Stanford university

Abstract

Extracellular vesicle microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ post-transplant lymphoproliferative disorder

Ayantika Sen1, Jeanna Enriquez1, Mahil Rao1, Carlos O. Esquivel1, Olivia M. Martinez1, Sheri M. Krams1.

1Department of Surgery, Stanford university, Stanford, CA, United States

CTOTC-06.

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors include primary Epstein-Barr virus (EBV) infection, reactivation of EBV in recipient B cells, and decreased T cell immunity due to immunosuppression. In our previous studies EBV infection was demonstrated to markedly alter the expression of host B cell microRNA (miR). Specifically, miR-194 expression was uniquely suppressed in EBV+ B cell lines from PTLD patients and the 3’untranslated region of IL-10 was determined to be targeted by miR-194.  Although EBV has been shown to regulate host miR expression in B cell lymphoma cell lines, the expression of miRs in the circulation of patients with EBV-associated PTLD has not been studied. We have shown that miR-194 is significantly decreased in EBV+PTLD tumors and that additional miRs, including miRs-17, 19 and 106a are also reduced in EBV+PTLD as compared to EBV-PTLD. We quantitated the levels of miRs-17, 19, 106a, 155, and 194 in the plasma and extracellular vesicles (EV; 50-70 nm as determined by nanoparticle tracking analysis) from pediatric recipients of solid organ transplants with EBV+ PTLD+ that were matched 1:2 with EBV+ PTLD- pediatric transplant recipients as part of the NIH-sponsored Clinical Trials in Organ Transplantation in Children, (CTOTC-06) study. Levels of miRs-17, 19, 106a, and 194 were reduced in the plasma and extracellular vesicles (EV) of EBV+ PTLD+ group compared to matched controls, with miRs-17 (p = 0.034; plasma), miRs-19 (p = 0.029; EV) and miR-106a (p = 0.007; plasma and EV) being significantly reduced. Similar levels of miR-155 were detected in the plasma and EV of all pediatric SOT recipients. Importantly, ~90% of the cell-free miR were contained within the EV supporting that EBV+ PTLD tumor miR are detected in the circulation and suggesting that EVs, containing miRs, may have the potential to target and regulate cells of the immune system. Further development of diagnostic, mechanistic and potential therapeutic uses of the miRs in PTLD is warranted.

 

NIH A1UO1AI104342. UM2AI117870 (Rho).. Transplant and Tissue Engineering Fellowship, Lucile Packard Children's Hospital, Stanford..


© 2024 IPTA 2023